Walden Group Healthcare M&A Blog

The Coming of Age of Gene Therapy

11/08/2019
In vivo gene therapy, the process of delivering genetic material into the body to cure disease, is a challenging area but has the potential to cure millions suffering from genetic conditions such as cystic fibrosis or muscular dystrophy. With a $40b plus market, gene therapy has the potential to be non-pathogenic to humans and prevent DNA damage...
Read More
In 2019 M&A Has Continued to Play a Critical Role in Growth Strategies

11/6/2019
• Boston Scientific acquired London-based BTG plc (maker of products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals) for $4b. • 3M closed its $6.7b deal of Acelity, a developer of wound care and specialty surgical management products, in October 2019. • J&J’s Ethicon...
Read More
Robotics Remain an Active M&A Area

11/4/2019
Earlier in 2019, Johnson & Johnson paid $3.4b (plus up to an additional $2.35b) for Auris Health, Inc., a maker of endoscopic robotic technologies. The Auris platform complements robotics currently in development for general surgery by Verb Surgical, a startup founded by J&J and Verily Life Sciences (an Alphabet unit), and for orthopedics...
Read More
FDA Grants Breakthrough Device Designation to Medtronic’s Minimally Invasive Valiant TAAA Stent Graft System

10/10/2019
The new Valiant TAAA Stent Graft System is designed to repair a thoracoabdominal aortic aneurysm (TAAA). A TAAA causes swelling of the aorta, which extends from the chest into the abdomen. Commonly, TAAA affects the branch arteries supplying blood to various internal organs. The condition accounts for approximately 15% of all thoracic aneurysms....
Read More
Celgene to Sell Blockbuster Drug to Amgen for $13.4b

08/26/2019
Amgen Inc., a $23b multinational biopharmaceutical company is buying the worldwide rights to Otezla® from Celgene Corporation, a $13b developer of therapies for cancer and inflammatory diseases, for $13.4b. The acquisition complements Amgen's existing inflammation franchise of innovative biologics and biosimilar products. Otezla® (apremilast) is...
Read More